[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"platelet-transfusion\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:platelet-transfusion":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,49,78,116],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100645419","effect-of-platelet-concentrate-transfusion-on-microcirculatory-endothelial-function-in-intensive-care-unit-100645419",false,"NCT07682246","EFFECT OF PLATELET CONCENTRATE TRANSFUSION ON MICROCIRCULATORY ENDOTHELIAL FUNCTION IN INTENSIVE CARE UNIT","EFFECT OF PLATELET CONCENTRATE TRANSFUSION ON MICROCIRCULATORY ENDOTHELIAL FUNCTION IN INTENSIVE CARE UNIT.","PLATOMIR","Inclusion Criteria:\n\n* Adult patient ≥ 18 years of age\n* Admitted to intensive care\n* Requires prophylactic platelet transfusion for thrombocytopenia\n* Enrolled in a social security program\n* No objection to participating in the study\n\nExclusion Criteria:\n\n* Recent platelet or red blood cell transfusion (\\\u003C 24 hours)\n* Need for urgent red blood cell transfusion due to active bleeding\n* Patient under guardianship or conservatorship\n* Significant peripheral edema","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","OBSERVATIONAL","This study aims to investigate the impact of platelet concentrate (PC) transfusions on endothelial function and the systemic inflammatory response in thrombopenic patients admitted to intensive care who require prophylactic platelet transfusions.\n\nEndothelial function will be measured using a laser Doppler device coupled with an acetylcholine iontophoresis system that is applied to the skin.",[25,26,27,28],"Thrombocytopenia","Prophylactic Platelet Transfusion","Platelet Transfusion","Endothelial Function",[30,31,27,28,32,33,34,35],"ICU","intensive care","endothelial biomarkers","systemic inflammation","oxidative stress","peripheral tissue perfusion","NOT_YET_RECRUITING","2026-06-26",{"date":39,"type":40},"2026-07-02","ACTUAL",{"date":42,"type":21},"2026-07",{"date":44,"type":21},"2027-07",{"name":46,"class":47},"Assistance Publique - Hôpitaux de Paris","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":58,"studyType":22,"phases":4,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":4},"100642137","role-of-viscoelastometric-testing-in-the-development-and-validation-of-a-clinical-biological-score-for-predicting-bleeding-in-patients-with-malignant-haematological-disorders-and-severe-thrombocytopenia-100642137","NCT07653672","Role of Viscoelastometric Testing in the Development and Validation of a Clinical-biological Score for Predicting Bleeding in Patients With Malignant Haematological Disorders and Severe Thrombocytopenia","VISCOTHEM-2","Inclusion Criteria:\n\n* Adult patients;\n* Who have been informed about the study and have freely given their informed consent to participate in the study;\n* With a malignant haematological disorder or bone marrow failure, whether treated or untreated and at any stage of treatment;\n* With central thrombocytopenia strictly below 20 G\u002FL in a blood sample taken less than 72 hours ago and not having received a transfusion since;\n* Admitted to a haematology day unit or inpatient ward, or being followed up at a haematology outpatient clinic;\n* With or without active bleeding;\n* Affiliated with or covered by a social security scheme.\n\nExclusion Criteria:\n\n* Patients who have received at least one of the following treatments:\n* Antiplatelet agents within 7 days prior to enrolment,\n* Vitamin K antagonists within 7 days prior to enrolment,\n* Direct oral anticoagulants within 72 hours prior to enrolment,\n* Low molecular weight heparin within 24 hours prior to inclusion,\n* Unfractionated heparin within 6 hours prior to inclusion,\n* Bruton's tyrosine kinase inhibitor (ibrutinib, zanubrutinib or acalabrutinib) within 72 hours prior to inclusion;\n* Patients with a history of thrombopathy;\n* Patients with a history of haemostatic disorders carrying a risk of haemorrhage or thrombosis;\n* Thrombocytopenia associated with immune thrombocytopenic purpura or disseminated intravascular coagulation;\n* Patients already enrolled in the study;\n* Pregnant or breastfeeding women;\n* Patients under guardianship or curatorship;\n* Patients who do not understand French;\n* Patients under judicial protection.",{"count":57,"type":21},410,"5 Days","The goal of this single-center, non-controlled, non-randomized exploratory clinical trial is To develop and validate a clinical-biological score (VISCOTHEM score) incorporating viscoelastometric tests parameters; based on an association study, and to establish a threshold that enables the prediction of the immediate risk of bleeding in haematology patients with severe thrombocytopenia (\\\u003C20 G\u002FL); with a view to selecting a population with a residual risk of bleeding of zero (NPV ≥ 95%, to achieve a residual probability of bleeding \\\u003C 5%).\n\nThe score may incorporate variables identified in the literature as having a plausible causal relationship with the occurrence of bleeding (14,15), as well as viscoelastometric tests parameters, conventional haemostasis parameters and relevant clinical parameters. .\n\nParticipants will undergo an additional blood sample to standard care. The total volume of blood drawn will be 21.1 mL. The following analyses will be performed: Quantra®, Rotem®, blood count, platelets, immature platelet count, plasma prothrombin time, activated partial thromboplastin time, International Normalized Ratio, fibrinogen, urea, creatinin, albumin.",[25,27,61,62],"Haemorrhage","Hematologic Malignancies",[64,65,66,67,68],"viscoelasticity test","thrombocytopenia","haematologic disease","risk of bleeding","clinical and laboratory score","2026-06-16",{"date":71,"type":40},"2026-06-17",{"date":73,"type":21},"2026-06-30",{"date":75,"type":21},"2028-07-15",{"name":77,"class":47},"Centre Hospitalier Annecy Genevois",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":85,"sex":17,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":90,"phases":91,"briefSummary":93,"conditions":94,"keywords":100,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":115},"100568106","neonatal-platelet-transfusion-threshold-trial-100568106","NCT06676904","Neonatal Platelet Transfusion Threshold Trial","NeoPlaTT","Inclusion Criteria:\n\n* Gestational age of 23 0\u002F7 to 26 6\u002F7 weeks\n* Postnatal age of \\\u003C 48 hours\n\nExclusion Criteria:\n\n* Comfort care or withdrawal of care planned\n* Neonatal alloimmune thrombocytopenia or suspected\u002Fconfirmed congenital platelet or bleeding disorder\n* Receipt of platelet transfusion\n* No receipt of Vitamin K\n* Parents\u002Fguardian decline consent",true,"1 Hour","48 Hours",{"count":89,"type":21},2433,"INTERVENTIONAL",[92],"NA","The objective of the NeoPlaTT trial is to test whether, among extremely preterm infants born at 23 0\u002F7 to 26 6\u002F7 weeks' gestation, a lower platelet transfusion threshold, compared to a higher threshold, improves survival without major or severe bleeding up to 40 0\u002F7 weeks' postmenstrual age (PMA).",[25,95,27,96,97,98,99],"Neonatal","Infant, Newborn, Diseases","Infant, Extremely Low Birth Weight","Infant, Small for Gestational Age","Thrombosis",[101,102,103],"platelet transfusion","neonatal","thrombosis","RECRUITING","2026-03-24",{"date":107,"type":40},"2026-03-25",{"date":109,"type":40},"2025-06-13",{"date":111,"type":21},"2031-04-30",{"name":113,"class":114},"NICHD Neonatal Research Network","NETWORK",20,{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":126,"conditions":127,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":48},"100620211","pathogen-reduced-platelet-concentrates-experience-in-routine-practice-in-germany-100620211","NCT07354672","Pathogen-Reduced Platelet Concentrates: Experience in Routine Practice in Germany","Pathogen-Reduced Platelet Concentrates: Experience In Routine Practice In Germany","INITIATE","Inclusion Criteria:\n\n* Patients ≥ 18 years\n* Patients who, based on clinical indications\\*, receive at least one platelet transfusion with a pathogen-reduced platelet concentrate for treatment of bleeding risk caused by severe thrombocytopenia resulting from impaired platelet production.\n\n(\\* Taking into account the Cross-sectional Guidelines on the transfusion of blood components and plasma derivatives issued by the German Medical Association (Bundesärztekammer) in its current version.)\n\nExclusion Criteria:\n\nPatients will not be included if they fulfil at least one of the following exclusion criteria:\n\n* Known hypersensitivity to amotosalen HCl or psoralens. In this case, platelet concentrates treated with this pathogen inactivation method should not be used.\n* Known allergies of the recipient to human plasma proteins.\n* Known immune thrombocytopenia.\n* Thrombotic microangiopathy (thrombotic thrombocytopenic purpura; haemolytic uremic syn-drome).\n* Post-transfusion purpura.\n* Heparin-induced thrombocytopenia.\n* Congenital platelet function disorders, such as Glanzmann's thrombasthenia or Bernard- Souli-er syndrome",{"count":125,"type":21},850,"* Overall objective: to accumulate further experience with the use of pathogen-reduced platelet concentrates throughout the entire process chain from manufacture to clinical use of pathogen-reduced platelet concentrates and their efficacy and safety under real-world conditions. The study aims to better understand the impact of pathogen inactivation on the various steps of the overall supply chain in routine practice, whereby safety, measured in terms of the frequency of serious transfusion reactions and the type, imputability, and outcome of the reactions, is the primary endpoint.\n* Study product: Pathogen-reduced platelet concentrates.\n* Methodology: multi-center, open-label, prospective, non-interventional safety study.",[27],"2026-01-12",{"date":130,"type":40},"2026-01-21",{"date":132,"type":40},"2025-12-22",{"date":134,"type":21},"2027-06",{"name":136,"class":47},"Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen"]